【佳学基因检测】实体瘤个体化医疗的新策略：分子标志物和临床试验设计

肿瘤基因检测需要多长时间香港

根据如何选择有效的靶向药物治疗认识到《Clin Cancer Res》在. 2014 Sep 1;20(17):4425-35.发表了一篇题目为《实体瘤个体化医疗的新策略：分子标志物和临床试验设计》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Juliane M Jürgensmeier , Joseph P Eder , Roy S Herbst 等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤标志物研究内容关键词：

实体瘤,个体化医疗,新策略,伴随检测,基因检测

肿瘤靶向治疗基因检测临床应用结果

了解肿瘤生物学的信号通路的描述，加上允许广泛分子谱分析和数据分析的技术的快速发展，导致了肿瘤学个性化医疗的新时代。现在，许多学术机构在提出治疗建议之前，定期在个性化医学肿瘤委员会会议上对患者进行分析并讨论他们的病例。制药公司发起的临床试验通常需要特定的基因检测标志物才能注册，或者至少为未来的标志物探索多种选择。除了少数被批准用于治疗组织学和分子明确的肿瘤患者的靶向药物外，大量正在开发的新型靶向药物正在进行临床研究，并通过基因检测进行伴随分析以确定反应贼佳的患者群体。尽管目前分析的重点在于遗传分析，但正在开发额外的 RNA、蛋白质和免疫参数测试并将其纳入临床研究，这些方法可能会对未来的患者选择和治疗方法做出重大贡献。随着肿瘤生物学和人类遗传学的进步已经确定了有希望的肿瘤靶点，正在进行的新药临床评估现在需要证明这一承诺是否可以转化为对患者的益处。

肿瘤发生与反复转移国际数据库描述：

The delineation of signaling pathways to understand tumor biology combined with the rapid development of technologies that allow broad molecular profiling and data analysis has led to a new era of personalized medicine in oncology. Many academic institutions now routinely profile patients and discuss their cases in meetings of personalized medicine tumor boards before making treatment recommendations. Clinical trials initiated by pharmaceutical companies often require specific markers for enrollment or at least explore multiple options for future markers. In addition to the still small number of targeted agents that are approved for the therapy of patients with histological and molecularly defined tumors, a broad range of novel targeted agents in development are undergoing clinical studies with companion profiling to determine the best-responding patient population. Although the present focus of profiling lies in genetic analyses, additional tests of RNA, protein, and immune parameters are being developed and incorporated in clinical research, and these methods are likely to contribute significantly to future patient selection and treatment approaches. As the advances in tumor biology and human genetics have identified promising tumor targets, the ongoing clinical evaluation of novel agents will now need to show if the promise can be translated into benefit for patients.